Inoviq Ltd

IIQ

Company Profile

  • Business description

    Inoviq Ltd is engaged in developing and commercializing a portfolio of diagnostic and exosome-based products to improve the diagnosis and treatment of cancer and other diseases. The company has commercialized the hTERT test used as an adjunct to urine cytology testing for bladder cancer and the EXO-NET pan-exosome capture tool for research purposes. Its cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast, prostate, and other cancers. The Group operates predominantly in one business segment, the research and development of cancer diagnostics, and two geographical segments, Victoria, Australia, and the United States of America, with the majority of revenue coming from Australia.

  • Contact

    23 Normanby Road
    Notting Hill
    MelbourneVIC3168
    AUS

    T: +61 395487586

    http://www.inoviq.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Diagnostics & Research

    Fiscal Year End

    30 June 2027

    Employees

    5

Stocks News & Analysis

stocks

Avoid these overvalued ASX shares

The two shares with the highest price to fair value in our Australian coverage.
stocks

Going into earnings, is Microsoft stock a buy, a sell, or fairly valued?

Watching AI monetization, capex’s impact on margins, and guidance on Azure.
stocks

Lithium’s latest drop and what it means for ASX investors

Volatility returns to the lithium market.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,004.9014.700.16%
CAC 408,437.8974.750.89%
DAX 4025,155.41144.060.58%
Dow JONES (US)52,218.586.06-0.01%
FTSE 10010,716.97131.061.24%
HKSE24,892.66239.63-0.95%
NASDAQ25,690.90146.30-0.57%
Nikkei 22566,115.60116.59-0.18%
NZX 50 Index13,716.8346.35-0.34%
S&P 5007,498.9610.24-0.14%
S&P/ASX 2008,823.0016.500.19%
SSE Composite Index3,867.032.670.07%

Market Movers